ArticleBMC pulmonary medicine2026
Machine learning-enabled diagnosis of viral respiratory infections from exhaled volatile organic compound analysis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe sensitivity and specificity of current breath biomarkers are often inadequate for effective requisite sensitivity for early-stage detection, thereby ignoring early-stage treatment in the patient.
methodsIn this study, we developed a screening model for viral respiratory infections using a combination of portable GC-MS and an artificial intelligence (AI) model. This platform employs machine learning algorithms to enhance the specificity and sensitivity of the model. Subsequently, we applied this platform to analyze 200 viral respiratory infections and normal exhaled samples.
resultsThe diagnostic signatures, including 1-nonanethiol and 2-butanone, generated by the model effectively discriminated viral respiratory infection patients from normal controls with high sensitivity (90%), specificity (81%), and accuracy (AUC = 0.85). Furthermore, propionaldehyde and amylaldehyde, generated by the model, effectively discriminated COVID-19 from influenza A patients with sensitivity (87.5%), specificity (75%), and accuracy (AUC = 0.80). Data from UKBiobank indicated that in the volatile metabolite profiles exhaled by patients with viral respiratory infections, some characteristic components are related to the metabolic products of the host’s fatty acid β-oxidation pathway.
conclusionThis study presents a diagnostic model that can identify novel and feasible breath biomarkers for detecting early-stage viral respiratory infections. The promising results position the platform as an efficient noninvasive screening test for clinical applications, offering potential advancements in early detection for viral respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.